Prana Biotechnology AGM Presentation

Prana Biotechnology Limited (ASX:PBT/NASDAQ:PRAN) will host a webcast of its Annual General Meeting on Friday, November 13, 2015, at 9.30am AEDT.

Prana Biotechnology Limited has released its Preliminary Final Report (Appendx 4E) for the 2014-15 financial year.

Prana Biotechnology yesterday announced its financial results for the 12 months to June 30, 2015.

Prana Biotechnology has today announced the safety outcomes of the IMAGINE Extension study in patients with Alzheimer’s disease. A 250mg dose of PBT2 was safe and well tolerated over a 2 year period. The independent Data Safety Monitoring Board did not identify any safety concerns related to PBT2.

Prana Biotechnology Limited has today announced that it has received a $6.8 million cash refund under the Australian Government’s R&D Tax Incentive Scheme.

Prana Biotechnology Limited has today announced that the European Commission has approved orphan designation for PBT2 for the treatment of Huntington’s disease, stating that Prana has shown that PBT2 might be of significant benefit for patients with Huntington’s disease.

Prana Biotechnology Limited today announced that the European Medicines Agency (EMA) has published the Minutes from the April 2015 Meeting of its Committee for Orphan Medicinal Products (COMP), detailing the recommendation from the COMP that PBT2 be granted Orphan Designation in Europe. Prana announced the positive COMP recommendation on 28 April, 2015.

Prana Biotechnology is pleased to announce the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion recommending designation of PBT2 for the treatment of Huntington disease as an orphan medicinal product to the European Commission (EC).

Prana Biotechnology has today announced the status of its End of Phase 2 discussions with the US Food and Drug Administration (FDA).